SHAN LIU

Patent Agent
Intellectual Property

EXPERIENCE:

Dr. Shan Liu is a patent agent in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. Shan focuses on patent prosecution, strategic patent counseling, and patent due diligence in the life sciences industry. She has extensive scientific experience in synthetic organic chemistry, drug discovery, physical chemistry, spectroscopy, carbohydrates, structural biology, and cancer biology.

Prior to joining the firm, Shan worked as a patent agent/technology specialist in a Boston-based law firm, where she drafted and prosecuted patent applications for pharmaceutical and biotechnology companies. Shan started her patent law career as a patent agent/fellow at the Office of Technology Development in the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH), where she evaluated vaccine inventions for patent protection, drafted research agreements, and marketed technologies for collaboration and licensing. While at the NIH, Shan completed the Foundation for Advanced Education in the Sciences (FAES) technology transfer certification program.

Shan received her Ph.D. in chemistry from the University of Georgia, where she synthesized small-molecule substrates and screened their interactions with a glycoprotein target for structure-based drug design. Subsequently, Shan joined the National Cancer Institute of the NIH and conducted her postdoctoral training in investigating protein-protein interactions involved in carcinogenesis.

EDUCATION:
  • J.D., George Washington University Law School (expected 2018)
  • Ph.D., Chemistry, University of Georgia, 2008
  • B.S., Chemistry, Beijing University of Chemical Technology, 2003
SELECT PUBLICATIONS:
  • Co-author, "FDA's Proposed Rules to Address Inaccurate Orange Book Use Codes May Shorten Approval Timelines for Select 505(b)(2) and Generic Drugs," Generic Pharma 2.0, July 15, 2015
  • Co-author with D.M. Hoffmeister, V. Norviel, P. Girinath, and C. Andres, "There's a Lot to Like About Hamburg's Legacy at the FDA," Law360, February 9, 2015
  • First author with Y. Chen, J. Li, T. Huang, S. Tarasov, A. King, A.M. Weissman, R.A. Byrd, and R. Das, "Promiscuous Interactions of gp78 E3 Ligase CUE Domain with Polyubiquitin Chains Aid Ubiquitination of Substrates," 20(12) Structure 2138-50, 2012
  • First author with L. Meng, K. Moremen, and J. Prestegard, "NMR Structural Characterization of the Substrates Bound to Alpha-2, 6-Sialyltransferase ST6Gal1," 48(47) Biochemistry 11211-11219, 2009
  • First author with A. Venot, L. Meng, F. Tian, K. Moremen, G. Boons, and J. Prestegard, "Spin-Labeled Analogs of CMP-NeuAc as NMR Probes of the Alpha-2, 6-Sialyltransferase ST6Gal1," 14(4) Chemistry & Biology (CELL) 409-418, 2007
ADMISSIONS:
  • U.S. Patent and Trademark Office

Contact Information

1700 K Street, NW
Fifth Floor
Washington, DC 20006
Phone | 202-973-8854

Email | Shan Liushliu@wsgr.com


Areas of Expertise

Print to PDF